Boston Scientific Corporation
BSX
$51.08
$0.621.23%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 21.00B | 20.62B | 20.08B | 19.35B | 18.49B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.00B | 20.62B | 20.08B | 19.35B | 18.49B |
| Cost of Revenue | 6.36B | 6.40B | 6.27B | 6.13B | 5.91B |
| Gross Profit | 14.64B | 14.21B | 13.81B | 13.22B | 12.58B |
| SG&A Expenses | 7.16B | 7.07B | 6.89B | 6.67B | 6.49B |
| Depreciation & Amortization | 918.00M | 910.00M | 897.00M | 894.00M | 874.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.59B | 16.51B | 16.10B | 15.63B | 15.11B |
| Operating Income | 4.41B | 4.11B | 3.97B | 3.72B | 3.39B |
| Income Before Tax | 3.86B | 3.74B | 3.38B | 3.27B | 3.00B |
| Income Tax Expenses | 192.00M | 183.00M | 492.00M | 485.00M | 502.00M |
| Earnings from Continuing Operations | 3.67K | 3.56K | 2.89K | 2.78K | 2.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.00M | 6.00M | 6.00M | 8.00M | 8.00M |
| Net Income | 3.68B | 3.57B | 2.90B | 2.79B | 2.51B |
| EBIT | 4.41B | 4.11B | 3.97B | 3.72B | 3.39B |
| EBITDA | 5.82B | 5.50B | 5.34B | 5.07B | 4.70B |
| EPS Basic | 2.48 | 2.40 | 1.96 | 1.89 | 1.70 |
| Normalized Basic EPS | 1.73 | 1.60 | 1.53 | 1.43 | 1.31 |
| EPS Diluted | 2.47 | 2.39 | 1.94 | 1.87 | 1.68 |
| Normalized Diluted EPS | 1.72 | 1.59 | 1.52 | 1.41 | 1.30 |
| Average Basic Shares Outstanding | 5.92B | 5.93B | 5.92B | 5.91B | 5.90B |
| Average Diluted Shares Outstanding | 5.96B | 5.98B | 5.98B | 5.97B | 5.96B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |